Leading UK Pharmacies trust Deltera
Deliver the non-live Shingrix vaccine to protect against herpes zoster. This PGD is essential for patients aged 50+ who want protection before they become eligible for the phased NHS programme.
A Fully Digital Clinical Platform
Integrated Bookings and Payments
Secure & Connected Patient Records
Ditch the paperwork with secure digital records. Deltera automatically shares treatment summaries with the patient’s and sends the required notification to their GP instantly.
Training and Eligibility Requirements
To ensure clinical safety and regulatory compliance, all practitioners using this PGD must meet the following professional standards:
- Professional Registration: Must be a registered healthcare professional (e.g., Pharmacist) with a valid GPhC or PSNI registration and personal professional indemnity insurance.
- Clinical Competency: Practitioners must be self-certified as competent in the specific clinical area covered by this PGD and stay up to date with relevant national guidelines (e.g., The Green Book or NICE clinical summaries).
- Mandatory Training: Current certification in Basic Life Support (BLS) and the management of anaphylaxis is required for all injectable services.
- PGD Authorisation: The practitioner must have read and signed the PGD document within the Deltera Clinical Dashboard, with the authorisation counter-signed by the designated organisational lead or Superintendent.
- Premises Standards: Services must be conducted in a private consultation room that meets national standards for patient confidentiality and clinical safety.
Speak to the clinicians behind the platform
We understand the complexities of PGDs and clinical governance in the UK. Schedule a meeting with our team to see how we can help you navigate the changing landscape of community pharmacy.
Access related PGDs
FAQs
Generally, anyone aged 50 or over. Deltera’s pre-screening logic specifically checks for previous shingles infections to ensure the vaccine is administered at the optimal time.
As a non-live vaccine, it is safe for more patients and provides longer-lasting protection. Deltera’s portal provides patients with clear advice on the benefits of this modern vaccine.
Shingrix is a 2-dose course. Deltera’s automated follow-up system ensures patients return 2–6 months later for their final dose, protecting your pharmacy's clinical outcomes.
Yes. The clinical advice in the Deltera portal explains how the vaccine reduces the risk of long-term nerve pain, a key selling point for private patients.
Still have questions?
Our team are here to support you.
Discover Deltera Practice Management
Deltera Practice Management digitalises your private pharmacy services, providing the complete pharmacy software package to offer a full range of Patient Group Directions (PGDs). Gain the oversight and efficiency you need to thrive.
